BioAmber, which converts renewable feedstocks into bio-succinic acid and other chemicals, raised $80 million by offering 8.0 million units at $10, the low end of the range of $10 to $12. The units consist of one common share and one warrant to purchase half a common share at $11 per whole common share. BioAmber plans to list the units on the NYSE under the symbol BIOAU, the common stock under the symbol BIOA and the warrants under the symbol BIOAWS. BioAmber also intends to list its common stock on the NYSE Euronext in Paris under the symbol BIOA. BioAmber initially filed confidentially on 11/9/2012. Credit Suisse, Societe Generale and Barclays acted as joint bookrunners on the deal.
